Bill
Bill > A2645
NJ A2645
NJ A2645Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.
summary
Introduced
01/13/2026
01/13/2026
In Committee
01/13/2026
01/13/2026
Crossed Over
Passed
Dead
Introduced Session
2026-2027 Regular Session
Bill Summary
This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency prior to the patient undergoing chemotherapy. Dihydropyrimidine dehydrogenase deficiency is a disorder in which the human body experiences difficultly or is unable to breakdown chemotherapy drugs leading to a harmful reaction. Under the bill, health insurance plans in this State are to cover expenses incurred in conducting one test for dihydropyrimidine dehydrogenase deficiency every year.
AI Summary
This bill mandates that physicians must offer patients a test for dihydropyrimidine dehydrogenase (DPD) deficiency before they begin chemotherapy, a condition where the body struggles to break down certain chemotherapy drugs, potentially causing severe reactions. Furthermore, health insurance plans in the state will be required to cover the cost of one DPD deficiency test annually for each patient, as well as any prescription drug treatments for the condition if the plan includes prescription drug benefits, ensuring these benefits are provided comparably to other medical conditions.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Introduced, Referred to Assembly Health Committee (on 01/13/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2026/A2645 |
| BillText | https://pub.njleg.gov/Bills/2026/A3000/2645_I1.HTM |
Loading...